Compugen Ltd. Announces Initial Validation Results for Two Novel Immunomodulatory Proteins and Further Results for CGEN-15001

TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ: CGEN) today reported the initial validation of two additional therapeutic product candidates, CGEN-15031 and CGEN-15051, in animal models of autoimmune diseases. These two novel molecules are soluble proteins based on two B7/CD28-like proteins discovered by Compugen, with each fusion protein combining the extracellular domain of one of the membrane proteins and an Fc antibody fragment. The results being announced today relate to the recently completed evaluation of the potential therapeutic activity of CGEN-15031 in an animal disease model of multiple sclerosis and of CGEN-15051 in a model of rheumatoid arthritis. The Compugen fusion proteins significantly ameliorated disease symptoms in these models and are predicted to have a potential use as protein therapeutics for multiple autoimmune diseases. The study of CGEN-15031 in the EAE model of multiple sclerosis was carried out in the laboratory of Prof. Stephen Miller at Northwestern University. CGEN-15051 was tested using the CIA model of rheumatoid arthritis at a commercial lab specializing in animal models of autoimmune diseases.